You have read all your free articles, to continue reading subscribe to read the rest of this content.
BioArctic has announced that the European Patent Office (EPO) has issued a decision to grant the European patent for novel antibodies that could be developed into a treatment for Alzheimer’s disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are linked to thAlready a subscriber Login…
Cantargia announces that the United States Patent and Trademark Office has granted the company's patent application directed to the product candidate CAN04. The antibody CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the iAlready a subscriber Login You have…
Asgard Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Asgard’s foundational patent related to the method of reprogramming cells towards the dendritic cell fate. The patent provides protection and market exclusivity of products based in the cellAlready a subscriber Login You have read all…
The company has been granted a patent from the European Patent Office, covering the treatment of fungal infections with compound glucono-δ-lactone (GDL). The patent is valid in 36 European countries and can be kept in force until the 6th of April 2037. Gedea Biotech has previously announced thatAlready a subscriber…
